PTGX Q1 2024 Earnings — Protagonist Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

PTGXProtagonist Therapeutics, Inc.

$6B

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$255M

Gross Profit

$255M100.0% margin

Operating Income

$206M80.9% margin

Net Income

$207M81.3% margin

EPS (Diluted)

$3.26

QoQ Revenue Growth

+324.9%

Cash Flow

Operating Cash Flow

-$27M

Free Cash Flow

-$28M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$629M

Total Liabilities

$69M

Stockholders' Equity

$560M

Cash & Equivalents

$173M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$255M	$0	—
Gross Profit	$255M	$0	—
Operating Income	$206M	-$36M	+672.7%
Net Income	$207M	-$34M	+714.8%

Revenue Segments

Development Services

$900,000100%